Literature DB >> 30235449

Clinical Characteristics and Prognostic Factors of Primary Splenic Angiosarcoma: A Retrospective Clinical Analysis from China.

Rong Li1,2, Ming Li1,2, Lin-Fang Zhang1,2, Xiao-Ming Liu1,2, Ting-Zi Hu1,2, Xiu-Juan Xia1,2, Jing-Shu Chi1,2, Xiao-Xia Jiang1,2, Can-Xia Xu1,2.   

Abstract

BACKGROUND/AIMS: Primary splenic angiosarcoma is an aggressive malignancy originating from endothelial cells with a particularly poor outcome despite radical therapy. Owing to its extremely low incidence, available data for splenic angiosarcoma are limited. The present study aimed to address this limitation by presenting a thorough retrospective analysis of Chinese primary splenic angiosarcoma patients over a 53-year period (1963-2016).
METHODS: To determine the characteristics of Chinese primary splenic angiosarcoma and identify factors that impact the outcomes of this histology, we retrospectively retrieved reports of 110 Chinese primary splenic angiosarcoma cases published between 1963-2012.
RESULTS: In total, 61 males and 49 females diagnosed with primary splenic angiosarcoma were included in the present study. The median age at diagnosis was 50 years (range 2.5-76 years). Of these patients, 25.5% had received prior radiotherapy. The rate of splenic rupture was 59.11%. The 1-year overall survival rate was 19.1% with a median overall survival time of 8.1 months. Age, gender, and radiation history showed no correlation with survival rate. However, by univariate analysis, we found that significant adverse predictors of survival were splenic rupture before surgery and large tumor size (> 5 cm), while adjuvant chemotherapy was a favorable predictor. Furthermore, multivariate analysis revealed that splenic rupture and adjuvant chemotherapy were independent adverse and favorable predictors, respectively.
CONCLUSION: Our large series describes and confirms the characteristics and poor prognosis of Chinese primary splenic angiosarcoma, thus indicating a critical role for early diagnosis and surgical intervention (prior to rupture) in management, and highlights the promising potential of adjuvant chemotherapy for improving the outcome in these cases.
© 2018 The Author(s). Published by S. Karger AG, Basel.

Entities:  

Keywords:  Chemotherapy; Clinical characters; Primary splenic angiosarcoma; Prognosis; Treatment

Mesh:

Year:  2018        PMID: 30235449     DOI: 10.1159/000493656

Source DB:  PubMed          Journal:  Cell Physiol Biochem        ISSN: 1015-8987


  4 in total

1.  Prognostic nomograms for predicting overall survival and cancer-specific survival in patients with angiosarcoma, a SEER population-based study.

Authors:  Ting Jiang; Zixiang Ye; Tianyu Shao; Yiyang Luo; Binbin Wang
Journal:  Sci Rep       Date:  2022-03-03       Impact factor: 4.379

2.  Treatment with sorafenib plus camrelizumab after splenectomy for primary splenic angiosarcoma with liver metastasis: A case report and literature review.

Authors:  Dan Pan; Tai-Ping Li; Jian-Hui Xiong; Shu-Bo Wang; Yao-Xu Chen; Jian-Feng Li; Qi Xiao
Journal:  World J Clin Cases       Date:  2022-03-26       Impact factor: 1.337

3.  Refractory splenic bleeding from splenic angiosarcoma: A case report and literature review.

Authors:  Tetsuro Kawazoe; Kippei Ohgaki; Eisuke Adachi; Yoichi Ikeda; Fumiyoshi Fushimi; Daisuke Kakihara
Journal:  Int J Surg Case Rep       Date:  2022-09-27

4.  Characteristics and survival outcomes of primary splenic cancers: A SEER population-based study.

Authors:  Yanna Lei; Qian Huang; Xiaoying Li; Xiufeng Zheng; Ming Liu
Journal:  Medicine (Baltimore)       Date:  2022-01-21       Impact factor: 1.889

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.